Estimated 3-year overall survival was 66%, disease-free survival was 58%, and the local control rate was 100%. No local recurrences had been seen at the longest follow-up of 160 months.
The Hopkins investigators compared their results with those from a pilot study using the same protocol at Massachusetts General Hospital in Boston. The MGH investigators had an 87% 5-year overall survival rate, 70% disease-free survival rate, and 92% local-control rate. Among MGH historical controls treated with surgery only, the respective rates were 58%, 42%, and 86%.
"This combined-modality approach to high grade soft-tissue sarcoma continues to play a role in the treatment of patients with this rare soft tissue neoplasm," the investigators concluded.
Both studies were internally funded. Dr. Ashman and Dr. Raval reported that they had no relevant financial disclosures.